Interleukin-6 -174G > C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS)

Basso, F., Lowe, G.D.O., Rumley, A., McMahon, A.D. and Humphries, S.E. (2002) Interleukin-6 -174G > C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arteriosclerosis, Thrombosis, and Vascular Biology, 22(4), pp. 599-604. (doi: 10.1161/01.ATV.0000013283.84306.1A)

Full text not currently available from Enlighten.


Interleukin (IL)-6 plays an important role in the pathogenesis of coronary heart disease (CHD). Two functional polymorphisms in the IL-6 promoter have been identified (-174G>C and - 572G>C), with both the rare alleles being associated with higher plasma levels of IL-6 after bypass surgery and one of them (-174G>C) associated with CHID risk, We have studied the contribution of these polymorphisms to CHID risk in the West of Scotland Coronary Prevention Study (WOSCOPS), a primary prevention trial that demonstrated the effectiveness of pravastatin in reducing morbidity and mortality from CHID. Four hundred ninety-eight cases (consisting of individuals experiencing a cardiovascular event during 4.8 years of follow- up) and 1109 controls (individuals matched for age and smoking habits) were genotyped. In the placebo group. there was no significant evidence of higher risk associated with the -174CC genotype compared with the GG+GC group. However, in the pravastatin-treated group, CC homozygotes had a significantly lower risk of CHD compared with the GG+GC placebo group (odds ratio 0.46. 95% Cl 0.27 to 0.79). and this remained statistically significant after adjustment for classic risk factors. Compared with the GG+GC group, men with the CC genotype had modestly, but not significantly. higher baseline levels of IL-6, C-reactive protein, or fibrinogen but showed a significantly greater fall in LDL cholesterol with statin treatment (P=0.036). The -572G>C polymorphism was not significantly associated with any plasma trait or CHD risk. Thus, in subjects under pravastatin treatment, the -174CC genotype was associated with a lower risk of CHID. These results demonstrate the importance of the inflammatory system in determining the risk of CHID and support the nonlipid effect of statins on risk.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Lowe, Professor Gordon
Authors: Basso, F., Lowe, G.D.O., Rumley, A., McMahon, A.D., and Humphries, S.E.
Subjects:R Medicine > RC Internal medicine
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher:American Heart Association

University Staff: Request a correction | Enlighten Editors: Update this record